Post-transfusion anemia

Article written and reviewed by Dr Luca Moretti

The descriptive expression anemia after transfusion refers to a new or persistent reduction in hemoglobin observed after administration of blood components; it is not a single disease entity, but a finding that requires identification of the responsible mechanism. Although blood transfusion is intended to treat anemia and restore oxygen carrying capacity, in some cases the patient paradoxically develops a new or persistent anemic state in the hours or days following the procedure. This scenario, which is often underrecognized in clinical practice, is particularly relevant in multiply transfused patients, patients with hemoglobinopathies or chronic diseases, and recipients of organ or bone marrow transplants.

Post-transfusion anemia occurs within a complex pathogenic framework in which immunologic, hematologic, infectious and metabolic factors interact, and in which adverse reactions to transfused red blood cells, early erythrocyte destruction and alterations of the bone marrow microenvironment are central to understanding and effectively managing the problem. A thorough assessment of pathophysiologic mechanisms, populations at risk and diagnostic and therapeutic strategies is essential to minimize the clinical impact of this condition and prevent potentially severe recurrences.

Pathophysiologic mechanisms and classification of forms

A decrease in hemoglobin after transfusion may result from multiple pathogenic mechanisms that overlap or alternate depending on the clinical context. Analysis of the pathophysiologic basis of this condition helps explain how a transfusion, rather than providing stable correction of the hemoglobin deficit, may sometimes trigger processes that worsen or perpetuate anemia, resulting in clinical presentations that are difficult to manage.

A first mechanism, particularly important in acute forms, is immune mediated destruction of transfused red blood cells. Specifically, the presence of preformed antibodies in the recipient against incompatible red cell antigens, often following previous transfusions, pregnancies or transplants, may trigger a rapid hemolytic response: transfused erythrocytes may be rapidly destroyed through complement mediated intravascular hemolysis, particularly typical of ABO incompatibility, or removed extravascularly by the reticuloendothelial system. This phenomenon classically occurs during transfusion or within 24 hours, often with a sudden decrease in hemoglobin, hemoglobinuria, hyperbilirubinemia and, in the most severe cases, acute kidney injury or hemodynamic shock. The severity of the reaction depends on antibody titer and specificity as well as the rate of erythrocyte destruction, and may be amplified by other predisposing conditions such as systemic inflammation or liver failure.

More insidious, but equally relevant, is the mechanism of delayed hemolysis. In this setting, typical of multiply transfused patients or patients with hemoglobinopathies, previously formed antibodies that have become undetectable may reappear through an anamnestic response; more rarely, new immunization develops. The reaction occurs more than 24 hours and up to 28 days after transfusion, most often within 5 to 14 days. This type of reaction may initially escape clinical recognition, presenting with a progressive decrease in hemoglobin, development of subclinical jaundice and increased indirect bilirubin; the reticulocyte response is variable and may include reticulocytosis or, particularly in some patients with sickle cell disease and hyperhemolysis, relative reticulocytopenia. In more complex cases, hyperhemolysis syndrome may develop, characterized by a fall in hemoglobin below the pretransfusion value and destruction of both transfused and autologous erythrocytes. Its pathogenesis is multifactorial and incompletely defined, and the syndrome may occur even without identifiable antibodies or with a negative DAT; it is particularly recognized in sickle cell disease, but is not limited to hemoglobinopathies.

Persistent anemia after transfusion is more often caused by the underlying disease, ongoing blood loss, hemolysis, inflammation, nutritional deficiencies or bone marrow failure. Transfusion may transiently reduce the erythropoietic stimulus, but it is not in itself a general clinical cause of persistent bone marrow suppression. In aplastic anemia, myelodysplastic syndromes or Parvovirus B19 infection, suppression of erythropoiesis may result in a state of "refractory anemia" in which each transfusion is only temporarily effective.

Another important cause of transfusion failure is persistent blood loss, often occult, as occurs with gastrointestinal bleeding, incompletely controlled surgical bleeding or complex coagulopathies. In these circumstances, transfusion cannot restore red cell mass in a stable manner, and the patient rapidly becomes anemic again.

Nonimmune causes are also important, including hemodilution after massive administration of crystalloid or colloid fluids, altered iron metabolism in patients with chronic disease, increased red cell destruction in inflammatory or ischemic environments and deficiency of substances essential for erythropoiesis. In some cases, particularly in older or critically ill patients, concomitant liver or kidney failure may profoundly alter erythrocyte survival and reduce the response to transfusion.

When evaluating a reduction in hemoglobin after transfusion, it is useful to distinguish acute onset mechanisms, such as an acute hemolytic transfusion reaction or persistent bleeding, from delayed mechanisms, such as a delayed hemolytic transfusion reaction; in persistent forms, the underlying disease, ongoing blood loss, hemolysis, inflammation, deficiencies or bone marrow failure should instead be investigated first. This is a temporal and pathogenetic distinction, not an independent nosologic classification.

In summary, the pathophysiology of post-transfusion anemia requires a comprehensive approach that considers both immunohematologic dynamics and the individual patient's clinical and metabolic factors. A thorough understanding of these mechanisms is essential to guide diagnostic and therapeutic strategies and minimize the risk of recurrence and progression to severe, potentially fatal forms.

Predisposing factors and populations at risk

Susceptibility to post-transfusion anemia is not uniform in the general population, but is influenced by a series of predisposing factors that act synergistically and produce marked variability in the incidence and severity of clinical manifestations. Understanding these determinants is essential not only to identify at-risk patients early, but also to plan preventive strategies and individualize post-transfusion monitoring.

A crucial role is played by red cell alloimmunization, a phenomenon of particular importance in multiply transfused patients, such as those with sickle cell disease, thalassemia, myelodysplastic syndromes and other hemoglobinopathies. In these populations, repeated exposure to different red cell antigens, together with individual genetic susceptibility, promotes formation of antibodies against "minor" antigens that are not always detected by conventional pretransfusion testing. The risk of alloimmunization and delayed hemolytic transfusion reactions increases in several multiply transfused populations; hyperhemolysis syndrome is particularly recognized in sickle cell disease and should not be generalized to all multiply transfused patients or patients with myelodysplastic syndrome.

Immunosuppression may modify the clinical presentation and coexist with bone marrow failure, but it is not a general predisposing factor for red cell alloimmunization. In patients with cancer receiving chemotherapy, transplant recipients and patients with chronic infections, persistent anemia after transfusion is more often due to the underlying disease, bone marrow suppression, inflammation or treatment; any hemolytic reaction must be documented using clinical and immunohematologic criteria.

Persistent blood loss, particularly when occult or underestimated, as in gastrointestinal bleeding, incompletely controlled surgical hemorrhage or coagulation disorders, is also an important determinant of transfusion failure. In these situations, the hemoglobin deficit tends to recur rapidly, negating the effectiveness of transfusion and requiring more intensive monitoring.

Alterations in iron metabolism and deficiency of erythropoietic cofactors, particularly iron, folate and vitamin B12, represent additional risk factors, especially in patients with chronic diseases, kidney failure, malnutrition or increased metabolic requirements. In these cases, the response to transfusion may be temporarily favorable, but anemia often recurs rapidly unless the underlying causes are corrected.

Finally, massive transfusions, typical of patients with major trauma, complex cardiac surgery and hemorrhagic emergencies, expose patients to an increased risk of hemodilution, disturbances of homeostasis and multiorgan dysfunction, indirectly contributing to the onset or persistence of refractory anemia.

In summary, the risk of post-transfusion anemia results from the convergence of multiple factors: previous transfusion history, genetic susceptibility, chronic diseases, hematologic and nutritional status, immune status and the acute clinical context. A multidimensional assessment of these factors is essential to identify patients at greatest risk promptly and adopt effective preventive strategies.

Clinical Manifestations

The clinical presentation of post-transfusion anemia is extremely heterogeneous and depends on multiple factors: the predominant pathophysiologic mechanism, time of onset, underlying clinical context and presence of comorbidities. In some cases the condition may develop insidiously and progressively, whereas in others it rapidly progresses to potentially fatal presentations requiring prompt diagnosis and multidisciplinary management.

In acute forms caused by an immune mediated hemolytic reaction, symptoms may appear during transfusion or within 24 hours and reflect rapid destruction of transfused erythrocytes; however, an acute fall in hemoglobin after transfusion may also result from ongoing bleeding or hemodilution. In this setting, the patient may suddenly develop fever, chills, low back pain, dyspnea, tachycardia and hypotension. Signs of hemoglobinuria, with red brown discoloration of the urine, progressive jaundice, oliguria or anuria may also occur, and in the most severe cases acute kidney injury or hemodynamic shock may develop. The clinical picture may mimic other transfusion complications, such as severe allergic reactions, febrile nonhemolytic transfusion reaction, TRALI, TACO or a septic transfusion reaction; ABO incompatibility or incompatibility involving other red cell antigens is instead a possible cause of an acute hemolytic transfusion reaction, not a separate differential diagnosis.

In delayed forms, symptoms emerge days after transfusion, often insidiously. The patient may report fatigue, palpitations, exertional dyspnea, progressive pallor and worsening exercise tolerance, while laboratory findings show a new decrease in hemoglobin associated with signs of hemolysis; the reticulocyte response may range from reticulocytosis to relative reticulocytopenia. In patients with hyperhemolysis syndrome, hemoglobin may fall rapidly and dramatically, often below pretransfusion levels, with possible signs of massive hemolysis and a high risk of multiorgan complications.

The clinical presentation may be further complicated by immunosuppression or bone marrow dysfunction. Bone marrow dysfunction may limit the reticulocyte response, while delayed hemolytic transfusion reactions may cause few symptoms and be recognized mainly through the fall in hemoglobin and laboratory evidence of hemolysis. An unexpected decrease in hemoglobin after transfusion therefore requires laboratory monitoring and immunohematologic evaluation, but does not by itself establish an adverse transfusion reaction.

A particular aspect of post-transfusion anemia is the possibility of a "chronic" and paucisymptomatic presentation in patients with persistent blood loss or deficiency of erythropoietic cofactors. In these cases, symptoms may be subtle and limited to mild fatigue, pallor, slight tachycardia or reduced functional performance, and anemia is often identified only through periodic complete blood count monitoring. In older patients or those with cardiovascular comorbidities, even a modest decrease in hemoglobin may precipitate heart failure, worsen preexisting angina pectoris or destabilize the overall clinical condition.

Clinical diagnosis is therefore based on the close temporal relationship between transfusion and onset of symptoms, recognition of signs of hemolysis, including jaundice, hemoglobinuria, increased indirect bilirubin and LDH and reduced haptoglobin, and assessment of comorbidities that may alter the presentation or mask typical signs. A detailed medical history, targeted physical examination and hematologic and biochemical monitoring are essential for early diagnosis and correct classification of the clinical form of post-transfusion anemia.

Investigations and Diagnosis

The diagnostic evaluation of post-transfusion anemia requires a sequential and integrated approach capable of distinguishing among the different clinical forms and promptly identifying the underlying pathophysiologic mechanisms. The first step is recognition of recurrent anemia or failure to correct anemia after transfusion, together with a close temporal relationship between the transfusion event and changes in hematologic parameters.

The complete blood count is the cornerstone of post-transfusion monitoring and allows quantification of changes in hemoglobin concentration, red blood cell count, hematocrit and any reticulocytosis. In suspected cases, a peripheral blood smear may reveal schistocytes, spherocytes or other morphologic abnormalities suggestive of hemolysis.

Biochemical assessment should include measurement of total and fractionated bilirubin, lactate dehydrogenase (LDH) and haptoglobin, and, when intravascular hemolysis is suspected, testing the urine for hemoglobinuria. Increased indirect bilirubin and LDH with reduced haptoglobin are sensitive indicators of active hemolysis, while hemoglobinuria suggests extensive red blood cell destruction.

When an immune mediated hemolytic reaction is suspected, a direct antiglobulin test is essential to detect antibodies or complement fractions bound to the erythrocyte surface. A positive test supports the suspicion of immune mediated hemolysis, but does not by itself identify antibody specificity or demonstrate a causal relationship with the transfusion; antibody identification, an eluate when indicated, comparison of pretransfusion and post-transfusion samples and the clinical context must be integrated. Identification of specific antibodies and phenotypic characterization of transfused erythrocytes are useful for guiding clinical management and preventing recurrence.

In patients with refractory anemia or a progressive decrease in hemoglobin without evidence of hemolysis, assessment of bone marrow function with bone marrow aspiration and, when necessary, bone marrow biopsy may be indicated to exclude aplastic anemia, myelodysplastic syndromes or viral infections such as Parvovirus B19. When occult blood loss is suspected, endoscopic evaluation, abdominal imaging or other second level investigations may be indicated to locate the source of bleeding.

The diagnostic pathway should also include monitoring of organ function parameters, including renal, hepatic and cardiac function, particularly in older or frail patients in whom post-transfusion anemia may rapidly precipitate multiorgan decompensation.

In summary, diagnosis of post-transfusion anemia is based on a rational sequence: early clinical recognition, laboratory confirmation of hemolysis or an inadequate response, exclusion of other causes of acute or chronic anemia, identification of predisposing factors and prognostic assessment, in order to establish prompt and individualized management.

Therapeutic management, prevention and prognosis

Management of post-transfusion anemia requires a multilevel strategy tailored to the pathophysiologic mechanism, severity of the clinical presentation and the patient's risk profile. The primary objective is rapid identification and control of the underlying cause, stabilization of vital functions and prevention of the most severe complications.

In acute immune mediated forms, immediate discontinuation of the transfusion is the essential first step, even when the reaction is only clinically suspected. Hemodynamic support, renal monitoring and treatment of complications are initiated. Glucocorticoids are not routinely indicated in every acute hemolytic transfusion reaction; immunoglobulins, rituximab or plasma exchange are reserved mainly for hyperhemolysis syndrome or selected severe and refractory immune mediated forms.

In delayed forms, treatment focuses on management of hemolysis and prevention of recurrence. When another transfusion is clinically necessary, red blood cell units are selected according to extended antigen typing, particularly in multiply transfused patients or those with hemoglobinopathies. In complex alloimmunization, management at specialized transfusion centers, a search for "rare" donors or immunomodulatory strategies may be required. In hyperhemolysis syndrome, further transfusions should be avoided whenever possible because they may worsen hemolysis; if clinically indispensable, they must be managed in a specialist setting. Combined immunosuppressive protocols are used together with close monitoring of hemoglobin, hemolysis markers and organ function. In patients with sickle cell disease and delayed hemolytic transfusion reaction with hyperhemolysis, intravenous immunoglobulin and corticosteroids constitute first line immunosuppressive treatment; eculizumab may be used as second line therapy in severe cases, while rituximab is considered mainly when prevention of additional alloantibody formation is required before future transfusions.

Refractory anemia requires identification and correction of factors limiting the erythropoietic response. In bone marrow suppression, in addition to etiologic treatment, for example treatment of viral infections such as Parvovirus B19 or discontinuation of myelotoxic drugs, iron, folate and vitamin B12 supplementation is indicated according to documented deficiencies and, when appropriate, recombinant erythropoietin may be used to promote recovery of erythrocyte production. In complex cases, the therapeutic pathway may also include multidisciplinary interventions with nutritional, physiotherapy and psychological support.

A crucial aspect is management of persistent blood loss, which must always be guided by an accurate etiologic diagnosis, including occult bleeding sources, coagulation abnormalities or surgical complications. Treatment includes both control of the bleeding source and correction of any underlying coagulopathies, while avoiding unnecessary transfusions, which increase exposure to alloantigens and other transfusion complications without correcting the source of blood loss.

For prevention, the most effective strategies include extended red cell antigen typing in all high risk patients, careful selection of blood units, planning of blood-sparing protocols for high risk surgery and careful monitoring of hematologic parameters after transfusion, with particular attention to early signs of hemolysis or failure to respond to therapy. Patient information and education, particularly for multiply transfused patients and those with chronic hematologic diseases, are essential to increase awareness and promote early diagnosis.

Prognosis varies considerably according to the timeliness of intervention, severity of the underlying disease and effectiveness of preventive measures. Acute immune mediated forms remain associated with a high risk of mortality and morbidity when they are not recognized, while chronic or refractory forms substantially affect quality of life, independence and long term outcomes, particularly in frail, immunocompromised or multiply transfused patients.

Complications

The complications of post-transfusion hemolytic reactions may include acute kidney injury due to hemoglobinuria, shock associated with a severe hemolytic reaction, disseminated intravascular coagulation and multiorgan failure. Anaphylactic shock is a distinct transfusion reaction, and hypovolemic shock requires volume loss rather than hemolysis itself.

Delayed hemolytic transfusion reactions may cause a new fall in hemoglobin; in patients who require additional transfusions, the presence of alloantibodies and possible formation of new alloantibodies after further exposure may make it progressively more difficult to obtain compatible units. In hyperhemolysis syndrome, the rapid reduction in hemoglobin may cause tissue ischemia, organ injury and death; infections are not a direct complication of the syndrome.

General transfusion complications are also important: severe allergic reactions, TRALI (Transfusion-Related Acute Lung Injury), TACO (Transfusion-Associated Circulatory Overload), transmission of infectious agents, progressive alloimmunization and the risk that further transfusion options may become unavailable in multiply transfused patients. All these conditions require early multidisciplinary assessment and individualized planning of subsequent interventions.

After a severe transfusion event, nonspecific psychological consequences such as anxiety or post-traumatic stress may occur; their presence must be assessed individually and does not represent a characteristic complication of post-transfusion anemia.

In conclusion, only integrated management, close monitoring and a proactive approach to prevention and early diagnosis can minimize the risk and severity of complications, optimizing prognosis and quality of life in patients affected by this complex condition.

References
1. Delaney M, Wendel S, Bercovitz RS, et al. Transfusion reactions: prevention, diagnosis, and treatment. Lancet. 2016;388(10061):2825–2836.
2. Pirenne F, Yazdanbakhsh K. How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions. Blood. 2018;131(25):2773–2781.
3. Carson JL, Stanworth SJ, Guyatt G, et al. Red Blood Cell Transfusion: 2023 AABB International Guidelines. JAMA. 2023;330(19):1892-1902.
4. Tormey CA, Hendrickson JE. Transfusion-related red blood cell alloantibodies: induction and consequences. Blood. 2019;133(17):1821-1830.
5. Hendrickson JE, Tormey CA. Understanding red blood cell alloimmunization triggers. Hematology Am Soc Hematol Educ Program. 2016;2016(1):446-451.
6. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood. 2012;120(3):528-537.
7. Hendrickson JE, Fasano RM. Management of hemolytic transfusion reactions. Hematology Am Soc Hematol Educ Program. 2021;2021(1):704-709.
8. Vlaar APJ, Toy P, Fung M, et al. A consensus redefinition of transfusion-related acute lung injury. Transfusion. 2019;59(7):2465-2476.
9. Mueller MM, Van Remoortel H, Meybohm P, et al.; ICC PBM Frankfurt 2018 Group. Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference. JAMA. 2019;321(10):983-997.
10. Foukaneli T, et al. Guidelines on the use of irradiated blood components. Br J Haematol. 2020;191(5):704–724.